Youtor
Targeting Cancer Pathways The Epigenetics Question
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=vmGzWHwIGyc
Participating Experts: Stephen B. Baylin, MD (Johns Hopkins), Charles Roberts, MD PhD, (Dana Farber), Ali Shilatifard, PhD (Northwestern) • ⬇️ Expand “Show More” to view abstract and table of contents • ℹ️ Explore epigenetics pathway diagrams: https://cst-science.com/cli7eg • Tumors are complex tissues in which the cancer cells evolve traits that promote their own survival and progression of the disease. Some of these traits involve epigenetic mechanisms to drive oncogenesis, stimulate tumor cell proliferation, and evasion of the immune system. This webinar explores how aberrant changes in epigenetic modification can affect the expression of key genes and contribute to the pathological progression of cancer. Topics include: • • The major epigenetic changes seen in tumor tissue • • How specific epigenetic pathways can be targeted for therapeutic intervention • • The role of histone modifications (methylation, acetylation, ubiquitylation, phosphorylation, and others) in tumor survival and progression. • Table of Contents • 0:00 Welcome and overview • 2:32 Stephen Baylin speaker profile • 3:18 Epigenetics – classical and modern • 4:52 Epigenomics hard drive and software • 5:53 Cancer and the Epigenome • 7:39 The position of mutations and the abnormal epigenome in tumor progression • 8:51 The hallmarks of cancer and therapy targets • 10:29 A trial of low dose epigenetic therapy for advanced NSCLC – what have we learned? • 11:32 Images of patient with partial response: hepatic metastases • 12:59 Potential for epigenetic Rx priming to immune tolerance therapy • 14:11 Immune tolerance • 14:54 Study design • 16:19 Viral defense – nucleotide sensing • 18:15 Hypothesis – epigenetic therapy sensitizing to immune checkpoint therapy • 19:35 Charles Roberts speaker profile • 20:27 SWI/SNF (BAF) chromatin remodeling complexes in cancer • 21:34 Rhabdoid tumors • 22:01 The SWI/SNF complex mobilizes nucleosomes • 22:53 Snf5 targeted mice develop aggressive cancers • 22:43 Frequent inactivating mutations of SWI/SNF complex subunitsd in a variety of cancers • 24:54 Rhabdoid tumors have the lowest somatic mutation rate across cancers analyzed so far at the Broad (~3000 exomes) • 25:51 Swi/Snf and polycomb: epigenetic antagonism? • 26:36 Ezh2 is essential for in vivo tumor formation after Snf5 inactivation • 27:33 Phase I trial: Complete response in a malignant rhabdoid tumor patient treated with and EZH2 inhibitor • 29:02 Project Achilles: ARID1B is the #1 dependency in ARID1A mutant cancer cells • 29:47 Residual SWI/SNF complexes can be a vulnerability in cancers containing a SWI/SNF subunit mutation • 31:14 Conclusions • 32:04 Ali Shilatifard speaker profile • 33:31 Cancer prevalence with age • 34:39 Enhancer malfunction in cancer • 35:43 Stem cells and epigenetic processes in cancer pathogenesis • 37:44 Chromosomal translocations in MLL and leukemogenesis? • 40:13 Examples of acute leukemia • 41:06 Model systems for study of MLL • 42:23 Purification of yeast Set1/COMPASS family of H3K4 methylases • 45:13 Cancer genes identified • 46:38 Enhancer/promoter looping in transcriptional activation • 47:39 Enhancer malfunction in upregulated activation of oncogene expression • 48:49 Question and answer • About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about • All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks • #Antibody #CSTWebinar
#############################
